• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 4. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to 3-(N,N-Dimethylamino)-D-alanine (CAS No. 206559-98-0)

3-(N,N-Dimethylamino)-D-alanine, identified by the Chemical Abstracts Service Number (CAS No.) 206559-98-0, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic synthesis. This amino acid derivative is characterized by its unique structural motif, which combines a D-alanine backbone with a N,N-dimethylamino substituent. Such structural features make it a versatile building block for the development of novel bioactive molecules, particularly in the realm of peptidomimetics and enzyme inhibition studies.

The significance of 3-(N,N-Dimethylamino)-D-alanine lies in its ability to modulate biological pathways through precise interactions with target proteins. The D-configured amino acid moiety introduces stereochemical complexity, which can be exploited to enhance binding affinity and selectivity in drug design. Meanwhile, the N,N-dimethylamino group serves as a hydrogen bond acceptor and a steric anchor, further refining the molecular recognition properties of the compound. These attributes have positioned it as a valuable reagent in synthetic chemistry, enabling researchers to construct intricate molecular architectures with therapeutic potential.

Recent advancements in computational chemistry and molecular modeling have shed new light on the pharmacophoric properties of 3-(N,N-Dimethylamino)-D-alanine. Studies employing quantum mechanical calculations have revealed that the N,N-dimethylamino group exerts a profound influence on the electronic distribution of the molecule, thereby modulating its reactivity and interaction with biological targets. Such insights have been instrumental in guiding the design of next-generation inhibitors for enzymes involved in metabolic disorders and infectious diseases. For instance, modifications to the dimethylamino substituent have been shown to enhance binding affinity towards proteases, paving the way for more effective antiviral and anticancer agents.

In parallel, experimental investigations have demonstrated that 3-(N,N-Dimethylamino)-D-alanine can serve as a precursor for peptidomimetic peptides, which mimic the structure and function of natural peptides while exhibiting improved stability and bioavailability. These peptidomimetics are particularly promising in the treatment of neurodegenerative diseases, where they can selectively interact with amyloid-beta plaques or tau aggregates without triggering off-target effects. The incorporation of 3-(N,N-Dimethylamino)-D-alanine into such mimetics has been associated with enhanced pharmacokinetic profiles, underscoring its utility as a pharmacological chaperone.

The synthesis of 3-(N,N-Dimethylamino)-D-alanine presents unique challenges due to its stereogenic center and nitrogen-rich functional groups. Traditional synthetic routes often rely on chiral auxiliaries or asymmetric catalysis to achieve high enantiomeric purity. However, recent innovations in enzymatic resolution and biocatalysis have offered more sustainable alternatives. For example, transaminases have been employed to introduce the dimethylamino group with high regioselectivity, while stereoselective desymmetrization strategies have enabled the efficient production of enantiomerically pure 3-(N,N-Dimethylamino)-D-alanine under mild conditions. These advancements not only improve yield but also align with green chemistry principles by reducing waste generation.

The therapeutic potential of 3-(N,N-Dimethylamino)-D-alanine has been further explored in preclinical models of inflammation and autoimmune diseases. By acting as a scaffold for immunomodulatory compounds, this amino acid derivative has demonstrated efficacy in dampening excessive inflammatory responses without compromising host defense mechanisms. The ability to fine-tune its pharmacological properties through structural modifications has made it an attractive candidate for personalized medicine approaches. Researchers are now investigating how variations in the dimethylamino group’s length and electronic environment can influence immune cell signaling pathways, offering tailored therapeutic strategies for patients with diverse disease profiles.

Looking ahead, the future applications of 3-(N,N-Dimethylamino)-D-alanine are likely to expand into emerging fields such as regenerative medicine and gene therapy. Its role as a building block for synthetic peptides extends beyond traditional drug development to include biomaterials that can promote tissue repair or deliver nucleic acid-based therapeutics. The compound’s compatibility with solid-phase peptide synthesis (SPPS) techniques further enhances its versatility, allowing for rapid screening of novel sequences with desired biological activities. As computational tools continue to refine our understanding of molecular interactions, 3-(N,N-Dimethylamino)-D-alanine is poised to play an integral role in next-generation drug discovery initiatives.

In conclusion, 3-(N,N-Dimethylamino)-D-alanine (CAS No. 206559-98-0) represents a cornerstone in modern medicinal chemistry due to its unique structural features and broad applicability across multiple therapeutic areas. Its ability to serve as both a synthetic intermediate and an active pharmaceutical ingredient underscores its importance in addressing unmet medical needs. With ongoing research uncovering new mechanisms of action and innovative synthetic methodologies, this compound is set to remain at the forefront of biochemical innovation for years to come.

• 739363-49-6((R)-2-Amino-3-(diethylamino)propanoic acid)
• 754167-24-3(3-(N,N-Diethylamino)-L-alanine)
• 16676-91-8(Alanine,3-(methylamino)-)
• 15920-93-1((S)-2-Amino-3-(methylamino)propanoic acid)
• 20790-78-7(3-(N-Methylamino)-D-alanine)
• 10138-99-5((2S)-2-Amino-3-dimethylaminopropanoic acid)
• 700801-50-9(3-(N,N-Diethanolamino)-L-alanine)
• 17463-44-4(Alanine,3-(methylamino)-)
• 16012-55-8(β-N-methylamino-L-alanine hydrochloride)
• 102029-69-6(4-AZA-DL-LEUCINE DIHYDROCHLORIDE)